Overview
Irritative hyperplasia of the oral mucosa refers to benign, proliferative lesions characterized by inflammation and cellular proliferation in response to chronic irritation or trauma. This condition commonly affects patients with ill-fitting dentures, sharp dental restorations, or persistent oral habits such as biting nails or cheek. Clinically significant due to its potential to cause discomfort, functional impairment, and aesthetic concerns, irritative hyperplasia can significantly impact quality of life. Early recognition and management are crucial as untreated lesions may progress and complicate prosthetic rehabilitation. Understanding and addressing the underlying irritants is essential in day-to-day practice to prevent recurrence and ensure optimal patient outcomes 2.Pathophysiology
Irritative hyperplasia arises from repeated mechanical or chemical irritation of the oral mucosa, triggering a cascade of inflammatory responses. Initially, chronic trauma activates resident fibroblasts and inflammatory cells, leading to the release of cytokines and growth factors such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β). These mediators stimulate epithelial proliferation and induce a fibrotic response, characterized by the accumulation of extracellular matrix components. Over time, this process can lead to the formation of hyperplastic and fibrous tissue, manifesting clinically as thickened, nodular, or ulcerated lesions. The involvement of cyclooxygenase-2 (COX-2) expression, as seen in conditions like oral submucous fibrosis, further exacerbates inflammation and tissue remodeling, highlighting the role of aberrant prostaglandin synthesis in perpetuating the hyperplastic state 4.Epidemiology
The incidence of irritative hyperplasia is not extensively documented in large epidemiological studies, but it is commonly observed in patients with long-term denture wear or those with persistent oral irritants. Age is a significant factor, with older adults more frequently affected due to prolonged use of dentures and increased susceptibility to mucosal trauma. Gender distribution appears relatively balanced, though specific risk factors such as smoking and alcohol consumption may skew prevalence in certain populations. Geographic variations are less pronounced, but cultural practices involving oral habits can influence local incidence rates. Trends suggest an increasing prevalence with aging populations and greater reliance on dental prosthetics 2.Clinical Presentation
Patients typically present with complaints of discomfort, pain, or functional limitations due to the presence of thickened, erythematous, or nodular lesions in the oral mucosa. Common sites include the buccal mucosa, tongue, and floor of the mouth, particularly under poorly fitting dentures. Symptoms can range from mild irritation to severe ulceration, affecting speech and mastication. Red-flag features include rapid growth, ulceration, bleeding, or signs of systemic involvement, which may necessitate further investigation to rule out more serious conditions such as malignancy. Early recognition of these symptoms is crucial for timely intervention 2.Diagnosis
The diagnosis of irritative hyperplasia involves a thorough clinical examination and patient history focusing on potential irritants. Specific diagnostic criteria include:Management
Initial Management
Second-Line Management
Specialist Referral
Contraindications
Complications
Prognosis & Follow-up
The prognosis for irritative hyperplasia is generally good with appropriate management, often leading to resolution or significant improvement within weeks to months. Key prognostic indicators include early intervention, complete removal of irritants, and adherence to follow-up care. Recommended follow-up intervals include:Special Populations
Key Recommendations
References
1 Ghabour O, Mohamed PA, Eldokmak MM, Ibrahim YM. In-vitro assessment of thermal stability, color stability, degree of conversion, nanozeolite and monomer release, and antibacterial effect in nanozeolite-filled 3D printed denture base resin. Journal of dentistry 2026. link 2 Berg RW, Goldman BM, Kurtz K, Schweitzer K, Kraut RA. Prosthodontic management of sulcoplasty and sialodochoplasty with a conforming surgical stent. Journal of prosthodontics : official journal of the American College of Prosthodontists 2008. link 3 Yoon ES, Han SK, Kim WK. Advantages of the presence of living dermal fibroblasts within restylane for soft tissue augmentation. Annals of plastic surgery 2003. link 4 Tsai CH, Chou MY, Chang YC. The up-regulation of cyclooxygenase-2 expression in human buccal mucosal fibroblasts by arecoline: a possible role in the pathogenesis of oral submucous fibrosis. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2003. link 5 Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Ashida Y et al.. Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis and rheumatism 2002. link 6 Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. The Journal of biological chemistry 1994. link